FBRX - NASDAQ

Forte Biosciences, Inc.

FBRX·NASDAQ

$16.74

-7.9%

HealthcareBiotechnology

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$232.47M

EPS-4.7100

P/E Ratio-3.55

Earnings Date08/13/2026

82.78M

Assets

34%

3Y+97.0%

5Y+35.0%

10Y+134.0%

21.79M

Total Liabilities

140%

3Y+585.0%

5Y+864.0%

10Y-23.0%

60.99M

Total Equity

16%

3Y+57.0%

5Y+3.0%

10Y+772.0%

Forte Biosciences, Inc. Funding & Solvency Profile

FBRX · NASDAQ

Current Assets

Cash & Cash Equivalents76.96M

Net Receivables817.00K

Inventory0.00

Other Current Assets2.81M

Total Current Assets81 M

Non-Current Assets

Property, Plant & Equipment129.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets2.06M

Total Non-Current Assets2 M

Total Assets

82.78M

Financial Health Analysis

Current Ratio

3.88x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.36x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

60 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Forte Biosciences, Inc. Balance Sheet

FBRX • NASDAQ

Forte Biosciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	77M	22.2M	12M	41.1M	42M	58.8M	6.9M	40.8M	35.9M	5.5M	8.2M
Short-Term Investments	0.0	36.1M	25.2M	0.0	0.0	0.0	12.8M	55.3M	52.8M	25.7M	50.8M
Cash & Short-Term Investments	77M	58.4M	37.1M	41.1M	42M	58.8M	6.9M	96.1M	88.7M	31.2M	58.9M
Net Receivables	817K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	817K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	2.6M	1M	341K	387K	1.1M	564K	0.0	0.0	0.0	0.0
Other Current Assets	2.8M	336K	165K	70K	89K	76K	3K	1.7M	1.9M	1.2M	1.3M
Total Current Assets	80.6M	61.3M	38.3M	41.5M	42.5M	59.9M	7.5M	97.7M	90.6M	32.5M	60.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	129K	77K	109K	0.0	0.0	97K	150.6K	4M	1.2M	743K	445K
Other Non-Current Assets	2.1M	138K	544K	486K	786K	1.2M	0.0	1.4M	227K	2.1M	1.5M
Total Non-Current Assets	2.2M	215K	653K	486K	786K	1.3M	150.6K	5.3M	1.4M	2.9M	2M
Total Assets	82.8M	61.6M	39M	42M	43.3M	61.2M	7.7M	103.1M	92.1M	35.4M	62.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	10M	4.9M	1.4M	1.2M	946K	1.2M	1.6M	3.4M	2M	1.7M	1.3M
Accounts Payable	10M	4.9M	1.4M	1.2M	946K	1.2M	1.6M	78.4K	2M	1.7M	1.3M
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	532.0	6.7M	0.0	0.0	0.0
Accrued Expenses	0.0	2.7M	1.3M	1.1M	812K	1M	175K	2.8M	2.5M	728K	524K
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2M	7.2M	600K
Capital Lease Obligations (Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-2.5M	0.0	0.0
Tax Payables	1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	-4.7M	36K	59K	79K	145K
Other Current Liabilities	10.8M	1.6M	947K	890K	0.0	0.0	168K	10.3M	8.1M	4.7M	3.4M
Total Current Liabilities	20.8M	9.1M	3.7M	3.2M	1.8M	2.3M	1.9M	16.5M	17.3M	14.4M	5.9M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	4M	26.2M	3.6M	13.8M	16.9M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36K	68K	108K
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-36K	0.0	0.0
Other Non-Current Liabilities	1M	0.0	0.0	0.0	0.0	0.0	6.5M	2.2M	0.0	126K	176K
Total Non-Current Liabilities	1M	0.0	0.0	0.0	0.0	0.0	10.5M	28.4M	3.7M	14M	17.2M
Capital Lease Obligations	0.0	0.0	0.0	0.0	0.0	0.0	4M	0.0	0.0	0.0	0.0
Total Liabilities	21.8M	9.1M	3.7M	3.2M	1.8M	2.3M	12.4M	44.9M	21M	28.4M	23.1M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	43.3M	61.2M	10.5M	5.7M	92.1M	131.4M	131.4M
Common Stock	13K	6K	36K	21K	15K	13K	1K	23K	20K	2K	2K
Additional Paid-In Capital	284.3M	206.5M	153.8M	125.8M	114.7M	110.4M	199K	274M	0.0	0.0	2.2M
Retained Earnings	-223.4M	-154M	-118.5M	-87M	-73.2M	-51.5M	-5M	-215.9M	-166.9M	-128M	-94.5M
Accumulated Other Comprehensive Income/Loss	3K	11K	4K	0.0	-43.3M	-61.2M	10K	-23K	-34K	-2.4M	-58K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	-10.5M	0.0	146M	6M	0.0
Total Stockholders' Equity	61M	52.5M	35.3M	38.8M	41.5M	59M	-4.8M	58.1M	71.1M	7M	39.1M
Total Equity	61M	52.5M	35.3M	38.8M	41.5M	59M	-4.8M	58.1M	71.1M	7M	39.1M
SUMMARY
Total Liabilities & Equity	82.8M	61.6M	39M	42M	43.3M	61.2M	7.7M	103.1M	92.1M	35.4M	62.2M
Total Investments	0.0	36.1M	25.2M	0.0	0.0	0.0	12.8M	55.3M	52.8M	25.7M	50.8M
Total Debt	0.0	0.0	0.0	0.0	0.0	0.0	8.8M	26.2M	10.8M	21M	17.5M
Net Debt	-77M	-22.2M	-12M	-41.1M	-42M	-58.8M	1.8M	-14.6M	-25.1M	15.5M	9.3M
Shares Outstanding	12,432,854	12,432,854	12,432,854	12,432,854	12,432,854	12,432,854	12,432,854	12,432,854	12,432,854	12,432,854	12,432,854

SEC Filings

FBRX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 02, 2026	May 29, 2026	2026	View Filing
S-3 S-3 N/A	June 02, 2026	June 02, 2026		View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 11, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 11, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	May 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 09, 2026	April 08, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 01, 2026	March 31, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 31, 2026	December 31, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 14, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 14, 2025	2025	View Filing

Showing 1 to 10 of 161 filings

Related Guides

Blog Categories

Continue your FBRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.